Filtros de búsqueda

Lista de obras de Tami Pilot-Matias

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

artículo científico publicado en 2013

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations

artículo científico publicado en 2007

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

artículo científico publicado en 2007

An interferon-free antiviral regimen for HCV after liver transplantation

artículo científico publicado en 2014

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

artículo científico publicado en 2015

Analysis of the humoral response to the flagellin protein of Borrelia burgdorferi: cloning of regions capable of differentiating Lyme disease from syphilis

artículo científico publicado en 1993

Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility

artículo científico publicado en 2011

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.

artículo científico publicado en 2018

Consensus oligonucleotide primers for the detection of GB virus C in human cryptogenic hepatitis

artículo científico publicado en 1996

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

artículo científico publicado en 2018

Determination of hepatitis E virus seroprevalence by using recombinant fusion proteins and synthetic peptides

artículo científico publicado en 1994

Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well

artículo científico publicado en 2009

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

artículo científico publicado en 2014

Discovery of fluorobenzimidazole HCV NS5A inhibitors

artículo científico publicado en 2016

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A.

artículo científico publicado en 2013

Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.

artículo científico publicado en 2017

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

artículo científico publicado en 2015

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

scientific article published on 01 October 2018

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

artículo científico publicado en 2017

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.

artículo científico publicado en 2017

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).

artículo científico publicado en 2017

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

artículo científico publicado en 2007

Exploratory study of oral combination antiviral therapy for hepatitis C.

artículo científico publicado en 2013

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection

artículo científico publicado en 2014

Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker

artículo científico publicado en 1996

GB virus C E2 glycoprotein: expression in CHO cells, purification and characterization

artículo científico publicado el 1 de agosto de 1997

Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis

artículo científico publicado el 1 de septiembre de 1995

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

artículo científico publicado en 2018

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

artículo científico publicado en 2017

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection

artículo científico publicado en 2018

Glucocorticoids regulate surfactant protein synthesis in a pulmonary adenocarcinoma cell line

artículo científico publicado en 1989

Hepatitis C virus drug resistance-associated substitutions: State of the art summary

artículo científico

Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir

scientific article published in PLoS ONE

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir

artículo científico publicado en 2015

High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.

artículo científico publicado en 2018

High potency improvements to weak aryl uracil HCV polymerase inhibitor leads

artículo científico publicado en 2013

High-level expression of recombinant human FK-binding protein from a fusion precursor

artículo científico publicado el 1 de junio de 1992

High-level synthesis of the 12-kDa human FK506-binding protein in Escherichia coli using translational coupling

artículo científico publicado el 30 de junio de 1993

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

artículo científico publicado en 2018

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro

artículo científico publicado en 2007

Identification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B, and GBV-C.

artículo científico publicado en 1996

Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

artículo científico publicado en 2007

Identification of two flavivirus-like genomes in the GB hepatitis agent

artículo científico publicado en 1995

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

artículo científico publicado en 2017

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

artículo científico publicado en 2017

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

artículo científico publicado en 2014

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

artículo científico publicado en 2014

In vitro translation, post-translational processing and secretion of pulmonary surfactant protein B precursors

artículo científico publicado en 1989

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

artículo científico publicado en 2017

Isolation of novel virus-like sequences associated with human hepatitis

artículo científico publicado el 1 de junio de 1995

Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans

artículo científico publicado en 1999

Molecular and serologic analysis in the transmission of the GB hepatitis agents

artículo científico publicado en 1995

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

artículo científico publicado en 2005

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

artículo científico publicado en 2004

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives

artículo científico publicado en 2012

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

artículo científico publicado en 2015

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

artículo científico

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial

artículo científico publicado en 2017

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial

artículo científico publicado en 2016

Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy

scientific article published on 19 March 2019

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)

Origin of GB-hepatitis viruses

artículo científico publicado en 1995

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

artículo científico publicado en 2014

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

scholarly article by Preethi Krishnan et al published October 2018 in Antimicrobial Agents and Chemotherapy

Prevalence of TT virus infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses

artículo científico publicado en 1999

Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction

artículo científico publicado en 1996

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease

artículo científico publicado en 2010

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients

artículo científico

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis

artículo científico publicado en 2015

Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients

artículo científico publicado en 2015

Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera

artículo científico publicado en 2006

Reply

artículo científico publicado en 2016

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

artículo científico publicado en 2018

Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.

artículo científico publicado en 2017

Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir

artículo científico publicado en 2015

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

artículo científico publicado en 2014

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

artículo científico publicado en 2019

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

artículo científico publicado en 2017

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease

artículo científico publicado en 2019

Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis

artículo científico publicado en 1996

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

artículo científico publicado en 2011

Sequence heterogeneity within the 5'-terminal region of the hepatitis GB virus C genome and evidence for genotypes

artículo científico publicado en 1996

Structure and organization of the gene encoding human pulmonary surfactant proteolipid SP-B

artículo científico publicado en 1989

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

artículo científico publicado en 2014

Two SP-C genes encoding human pulmonary surfactant proteolipid

artículo científico publicado en 1988

cDNA and deduced amino acid sequence of human pulmonary surfactant-associated proteolipid SPL(Phe)

artículo científico publicado en 1987

cDNA, deduced polypeptide structure and chromosomal assignment of human pulmonary surfactant proteolipid, SPL(pVal)

artículo científico publicado en 1988